top biopharmaceuticals for glp-1 medication North America Glucagon-like Peptide-1 Agonists Companies GLP-1 Boost Supplement for Women

We forecast one to two GLP-1 launches annually starting in 2026, with the first oral entrant expected by 2027

Oral GLP-1 Formulations and Future Projections Several companies are developing oral GLP-1 formulations, including Novo Nordisk, Pfizer, and smaller firms, positioning them as potential acquisition targets

At the same time, obesity is showing up more often across the world, and there is also more public awareness about obesity related health complications which, is pushing people toward better solutions

Pfizer Inc

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

NO.6 Darzalex Company: Johnson & Johnson 2024 worldwide sales forecast: $11.98 billion Darzalex (Daratumumab) is a novel, high-affinity, therapeutic human monoclonal antibody against unique CD38 epitope with broad-spectrum killing activity